Breast Archives - Virginia Cancer Specialists

ALERT: COVID19 Update: For your safety, you will be asked to use a mask, if you do not have one, a mask will be provided. If a person presents with a temperature, you will be asked to return home and further instructions will be given by your health care team. For our patient’s protection, no visitors under 18 will be allowed in the offices, there is a limit one (1) visitor per patient if necessary. No visitors are allowed in the chemo infusion room. Telemedicine visits are available for routine office visits.

All Patients – Very Important: Regardless of vaccination status. If you are experiencing a fever or cold-like like symptoms, which also include GI Symptoms and Diarrhea, you should contact your Virginia Cancer Specialists Advice Line before visiting our clinics for scheduled appointments. This includes symptoms of respiratory illness, such as coughing or difficulty breathing. More Information-PLEASE CLICK HERE

Search Our Trials

At Virginia Cancer Specialists (VCS), research is a vital part of our mission to provide patients access to advanced cancer treatments and clinical trials in the community where they live and work.

Visit Clinicaltrials.gov Virginia Cancer Specialists Search for more information

Find A Clinical Trial

Disease Type: Breast

Trial ID 20284

Sponsor ID Seattle Genetics, Inc.

A Single Arm, Open Label Phase 2 Study of Tucatinib in Combination with Trastuzumab Deruxtecan in Subjects with Previously Treated Unresectable Locally-Advanced or Metastatic HER2+ Breast Cancer (SGNTUC-025)

Principal Investigator

Anne Favret, MD

1 Location

Trial ID 19049

Sponsor ID Genentech, Inc.

The main purpose of this study is to learn if the usual chemotherapy given before surgery (neoadjuvant therapy) for breast cancer plus the experimental drug, atezolizumab, is better than the usual chemotherapy plus a placebo. (A placebo is a drug that looks like the study drug but contains no medication.) The usual chemotherapy in this…

Principal Investigator

Anne Favret, MD

5 Locations

Trial ID 19058

Sponsor ID

CLEE011O12301C (TRIO033): A phase III, multicenter, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, early breast cancer (New Adjuvant TriAl with Ribociclib [LEE011]: NATALEE).

Principal Investigator

Alexander I Spira, MD, PhD, FACP

1 Location

Trial ID 19054

Sponsor ID

Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (SGNTUC-016)

Principal Investigator

Christina Brzezniak, DO

5 Locations

Trial ID DS8201-A-U303

Sponsor ID DS8201-A-U303

A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED TRIAL OF DS-8201A, AN ANTI-HER2-ANTIBODY DRUG CONJUGATE (ADC), VERSUS TREATMENT OF PHYSICIAN’S CHOICE FOR HER2LOW, UNRESECTABLE AND/OR METASTATIC BREAST CANCER SUBJECTS

Principal Investigator

Neelima Denduluri, MD, FASCO

1 Location

Trial ID 14059

Sponsor ID

Phase I/II trial of Ibrutinib plus Trastuzumab in HER2-amplified Metastatic Breast Cancer

Principal Investigator

Alexander I Spira, MD, PhD, FACP

1 Location

Trial ID 18282

Sponsor ID

Phase 3 Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician’s Choice (TPC) in subjects with Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) who have failed at least two prior chemotherapy regimens (IMMU-132-09)

Principal Investigator

Christina Brzezniak, DO

5 Locations

Trial ID DS8201-A-U301

Sponsor ID DS8201-A-U301

A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY OF DS-8201A (TRASTUZUMAB DERUXTECAN), AN ANTI-HER2-ANTIBODY DRUG CONJUGATE, VERSUS TREATMENT OF INVESTIGATOR’S CHOICE FOR HER2-POSITIVE, UNRESECTABLE AND/OR METASTATIC BREAST CANCER SUBJECTS PRETREATED WITH PRIOR STANDARD OF CARE HER2 THERAPIES, INCLUDING T-DM1

Principal Investigator

Neelima Denduluri, MD, FASCO

1 Location

Trial ID 18232

Sponsor ID

(AB928CSP0002) A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Breast or Gynecologic Malignancies

Principal Investigator

Alexander I Spira, MD, PhD, FACP

1 Location

Trial ID SIDE-OUT 3

Sponsor ID

Utilizing Multiomic Advanced Diagnostics to Identify Palbociclib Response Predictors and a Post-treatment Multiomic Signature for Patients with ER+/HER2- Metastatic Breast Cancer

Principal Investigator

Neelima Denduluri, MD, FASCO

6 Locations

1